- Home
- FSP vs LPCN Comparison
FSP vs LPCN Comparison
Compare FSP & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | LPCN |
|---|---|---|
| Founded | 1981 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 61.8M |
| IPO Year | 2001 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FSP | LPCN |
|---|---|---|
| Price | $0.66 | $2.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 551.1K | ★ 671.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.03% | N/A |
| EPS Growth | 15.69 | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $1,976,677.00 |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $1.81 |
| 52 Week High | $1.88 | $12.37 |
Technical Indicators
Market Signals| Indicator | FSP | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 27.42 |
| Support Level | $0.56 | N/A |
| Resistance Level | $0.71 | $3.40 |
| Average True Range (ATR) | 0.06 | 0.45 |
| MACD | 0.01 | -0.54 |
| Stochastic Oscillator | 62.95 | 4.81 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.